Preimplantation genetic screening (PGS) is used to determine embryonic aneuploidy. Transferring of aneuploid embryos leads to universally undesired outcomes such as failed embryo implantation, miscarriage or birth of trisomic offspring. Therefore, during the IVF process, applying PGS allows for informed decisions regarding the ploidy of which embryo(s) to transfer.
BlastoGen is now offering advanced Preimplantation Genetic Screening (PGS) with the latest OPTIMIZED technology using array Comparative Genomic Hybridization (aCGH). The primary advantage of aCGH is the ability to simultaneously detect aneuploidies, deletions, duplications and unbalanced translocations with a rapid turnaround. Array-CGH uses thousands of small segments of DNA as targets for each chromosome for analysis.
BlastoGen has performed comprehensive validation with known karyotyped cells to produce high level of accuracy, reproducibility, sensitivity and specificity and is committed to the highest standards of integrity, quality and service.